Amyloidosis Therapeutic Treatment Market Size & Forecast 2032

Market Insights

• Between 2024 and 2032, the global amyloidosis therapeutic treatment market is expected to develop at a compound annual growth rate (CAGR) of 7.60%, from its estimated USD 2251.2 million in 2023 to USD 4352.35 million in 2032.
• The significant type of amyloidosis category is AL amyloidosis (primary amyloidosis). On the other hand, ATTR amyloidosis (hereditary and wild-type) is expected to grow at a strong CAGR.
• Chemotherapy is anticipated to have the highest compound annual growth rate during the forecast period.
• The CAGR for newly diagnosed patients is expected to be the highest during the projection period.
• North America dominated the amyloidosis therapeutic treatment market.
• Regarding the market share of amyloidosis therapeutic treatment, Europe is expected to come second.
• Asia Pacific is anticipated to grow fastest in the amyloidosis therapeutic treatment market.
• The primary drivers of the market are the identification of trustworthy biomarkers for early detection and surveillance, the identification of the genetic variables influencing the development of amyloidosis, and the development of imaging techniques for improved disease visualization.
• The market is growing due to developments in gene editing technologies such as CRISPR, which are used to target and correct genetic mutations linked to amyloidosis. Additionally, research into immunotherapeutic approaches is being conducted more extensively.

Executive Summary

Market Definition

The formation of amyloids, or protein aggregates, that fold incorrectly and accumulate in different organs is the hallmark of a rare group of disorders known as amyloidosis. The gastrointestinal tract, soft tissue, liver, kidneys, and heart are the organs most commonly impacted. This is an incredibly rare metabolic disorder that affects the structure and function of organs and tissues, potentially leading to fatal illnesses; when amyloid protein accumulates in tissues and organs, a disorder known as amyloidosis develops.

Market Overview

The amyloidosis therapeutic treatment sector is estimated to develop at a 7.60% compound annual growth rate (CAGR) between 2024 and 2032, maintaining its current upward trend. The market will keep developing, rising from its estimated value of USD 2251.2 million in 2023 to USD 4352.35 million in 2032.

Research and development initiatives help scientists better understand the basic mechanics of amyloidosis, including the discovery of specific proteins involved in forming amyloid deposits. This information is crucial for creating tailored treatments that can halt the progression of the illness. Research aims to find biomarkers for amyloidosis, which are quantifiable signs of the disease's occurrence or progression. Biomarkers can help with early diagnosis, tracking the course of a disease, and determining how well a treatment works. These findings may lead to developing sophisticated diagnostic instruments, enabling prompt intervention. The ongoing advancements in drug discovery technologies enable scientists to find and create new compounds targeting amyloidosis-related pathways. This includes creating therapeutic agents such as antibodies and small molecules that can influence or prevent the buildup of amyloid deposits.

Additionally, developments in molecular biology and genetics aid in identifying genetic variables and mutations linked to various forms of amyloidosis. This information helps to improve therapeutic outcomes by enabling the development of customized treatments based on particular genetic profiles. Progress in R&D adds to the scientific data that regulatory bodies need to assess and authorize novel therapies. Together, researchers and regulatory agencies can expedite the approval process and the delivery of effective therapies to patients.

Segmentation by Type of Amyloidosis

• AL amyloidosis (primary amyloidosis) is the market leader by type of amyloidosis. Particularly, amyloid fibrils originating from aberrant immunoglobulin light chains (AL) generated by bone marrow-derived plasma cells are deposited in AL amyloidosis. One subset of white blood cells called plasma cells is responsible for the immune system's production of antibodies.
• The ATTR amyloidosis (hereditary and wild-type) category will exhibit a sizable CAGR during the projected period. The abnormal buildup of amyloid proteins in different body tissues and organs is the hallmark of a rare group of diseases called amyloidosis. One particular kind of amyloidosis involving the accumulation of transthyretin protein is ATTR (transthyretin) amyloidosis.
• Another type of amyloidosis, such as AA amyloidosis (secondary amyloidosis), also contributes to the market demand for therapeutic amyloidosis treatment.

Segmentation by Treatment Modalities

• Chemotherapy is more popular in the amyloidosis therapeutic treatment market. One of the therapeutic approaches used to treat amyloidosis is chemotherapy. A set of uncommon illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different body tissues and organs.
• The immunomodulatory drugs (IMiDs) category will likely register a significant CAGR during forecasting. Because of their anti-inflammatory qualities, IMiDs can help regulate the immune response, especially regarding inflammatory cytokine production.
• Monoclonal antibodies, TTR stabilizers, RNA interference (RNAi) therapies, liver transplantation, and supportive care also contribute to the demand for amyloidosis therapeutic treatment market.

Segmentation by Disease Severity

• The newly diagnosed patients category is projected to grow at the fastest rate over the projection period. A collection of uncommon illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different organs and tissues. The goals of therapeutic interventions for recently diagnosed amyloidosis patients are to control symptoms, reduce the rate of disease progression, and enhance overall quality of life.
• Other disease severity, including relapsed or refractory disease and advanced disease, also influence the need for the amyloidosis therapeutic treatment market.

Segmentation by Region

• North America dominates the market for amyloidosis therapeutic treatment. This is brought on by the ongoing research and development of increasingly sophisticated amyloidosis treatment medications, as well as an increase in the population's genetic susceptibility to the disease.
• Europe is estimated to rank second in market size for amyloidosis therapeutic treatment.
• The amyloidosis therapeutic treatment industry is predicted to flourish rapidly in Asia.
• The remaining requirement for amyloidosis therapeutic treatment is covered by world regions such as Africa, the Middle East, and Latin America.

The market for amyloidosis therapeutic treatment is believed to be significantly influenced by the growing elderly population for several interrelated reasons. A disorder called amyloidosis is defined by an abnormal buildup of amyloid proteins in tissues and organs. The risk of developing amyloidosis rises with age, so an important target market for this market is the elderly population. Diagnoses of amyloidosis are more common in older people. The likelihood of developing diseases linked to amyloidosis, such as Alzheimer's disease or systemic amyloidosis, rises with age. This increased incidence among older people directly impacts the need for treatments.

Based on projections, North America holds a significant market share of over 65%. North America is dominant worldwide due to a developed healthcare ecosystem and rising awareness of amyloidosis. The demand for amyloidosis treatments is expected to be highest in the United States in North America due to the country's large investments in medical research and development and the expanding availability of innovative treatments. With first-rate hospitals, academic institutions, and clinical trial capabilities, North America has a sophisticated and well-established healthcare infrastructure. The availability of state-of-the-art technologies and knowledgeable medical personnel facilitates the quick development and uptake of amyloidosis treatment options.

The amyloidosis therapeutic treatment market in Asia Pacific will expand fastest throughout the forecast. Economic growth has increased Population disposable income in many Asia Pacific countries. People can now afford to spend more on healthcare, including treating uncommon illnesses like amyloidosis. The expanding middle class is an important factor driving demand for sophisticated, pricy therapeutic treatments. The governments of the Asia-Pacific area are proactively addressing the difficulties encountered by patients with rare diseases. This involves putting laws and programs in place to help people who suffer from uncommon illnesses like amyloidosis. Government funding priorities for research, development, and access to cutting-edge therapies are making it more favorable for pharmaceutical companies to invest in developing treatments for amyloidosis.

Key Highlights of the Report

The global amyloidosis therapeutic treatment market is segmented by type of amyloidosis, treatment modalities, disease severity, and region. Regarding the type of amyloidosis, AL amyloidosis (primary amyloidosis) is the market spearhead. Chemotherapy is a significant category. The newly diagnosed patients category is anticipated to increase at the highest CAGR throughout the projection period. The amyloidosis therapeutic treatment market is expanding mostly in North America.

The disease's rising prevalence largely drives the market for amyloidosis therapeutic treatment. A collection of uncommon and complicated illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different organs and tissues. Several factors cause the increasing incidence of amyloidosis. Dietary practices, lifestyle modifications, and general health trends can influence the incidence of amyloidosis. Amyloidosis is more common because of a possible rise in the prevalence of conditions that make people more susceptible to the disease as global health patterns change. Although amyloidosis is thought to be a rare disease, precise prevalence estimates are difficult due to the disease's complexity and variety of forms.

The North American region is expected to account for the largest amyloidosis therapeutic treatment market globally. Policy initiatives, including expedited approval procedures, tax breaks for pharmaceutical firms, and research grants, have encouraged capital to be invested in creating treatments for uncommon diseases like amyloidosis. The Asia Pacific is also assumed to have the market's sharpest growth. Governments throughout the Asia-Pacific area are realizing more and more how critical it is to assist patients suffering from uncommon illnesses like amyloidosis. As a result, initiatives to offer financial support, enhance access to healthcare services, and finance research into more effective treatments for these conditions have been launched.

Which Key Factors Are Driving The Global Amyloidosis Therapeutic Treatment Market?

The main factors driving the market for amyloidosis therapeutic treatment are understanding the prevalence and distribution of the disease, examining the effectiveness of combining different therapeutic approaches, and advancements in drug discovery technologies like high-throughput screening.

What Are The Main Challenges Confronting The Amyloidosis Therapeutic Treatment Market Globally?

The primary barriers impeding the global amyloidosis therapeutic treatment industry are the need for sufficient knowledge regarding the underlying molecular mechanisms and pathophysiology and the commercial community's limited interest in creating treatments for uncommon diseases.

What Market Opportunities Exist For Amyloidosis Therapeutic Treatment Globally?

The potential for the amyloidosis therapeutic treatment market is driven by the investigation of enzyme replacement to address enzymatic deficiencies associated with specific types of amyloidosis and the use of nanotechnology for targeted drug delivery to specific tissues affected by amyloidosis.

Market Drivers

Multiple factors propel the amyloidosis therapeutic treatment industry across the globe. The primary factors propelling the global amyloidosis therapeutic treatment market are as follows:

Increasing Global Population of Elderly Individuals

During the projection period, an increase in transthyretin amyloidosis incidence is anticipated due to the nation's aging population. Based on NCBI data, wild-type ATTR, another name for an age-related form of amyloidosis, is primarily heart-related. In 2020, about 727 million people in the world were 65 years of age or older. By 2050, there will likely be 1.5 billion senior people worldwide, expanding at a 16.0% annual pace. This factor aids market expansion. Multiple comorbidities are common in older people, which complicates the management of amyloidosis. The co-existence of additional medical conditions could make treatment more difficult and necessitate specialized therapeutic approaches that deal with both amyloidosis and other age-related health problems. Older adults frequently need more resources and services in the healthcare system. Because older adults are more likely to have amyloidosis, there is a greater need for treatments to effectively manage and treat the disease, which drives up healthcare facility utilization.

Market Restraints

There are several obstacles that the global amyloidosis therapeutic treatment market must overcome to continue growing. Among them are the following:

Complexity of Illness and its Identification

The primary reason impeding the market expansion for amyloidosis therapeutic treatments is the disease's intricacy, both in terms of the illness itself and the diagnostic procedures. The inappropriate buildup of amyloid proteins in multiple organs indicates a rare set of disorders collectively known as amyloidosis. Distinct organ systems are affected by distinct forms of amyloidosis, each connecting to particular proteins. Establishing a therapy technique that works for everyone is difficult due to this variety. Amyloidosis symptoms might cross over into other, more prevalent conditions. This overlap can result in delayed or incorrect diagnoses, preventing patients from getting the right care when needed. This factor will restrain the development of the amyloidosis therapeutic treatment market.

Opportunities

There are plenty of potential prospects in the global amyloidosis therapeutic treatment industry. Among these are the following:

Increase In The Number Of Government Initiatives

Numerous programs launched by governmental and non-governmental organizations to raise public awareness of the illness and the advantages of treatment are expected to increase early diagnosis and treatment rates. To raise awareness of the disease among several medical professionals and ATTR amyloidosis patients, the Australian Amyloidosis Network, for example, arranged a biennial touring workshop in May 2021. The objective was to help patients and doctors comprehend the complexities of the disease, which will aid in the creation of novel treatments for transthyretin amyloidosis. Since amyloidosis is frequently regarded as a rare disease, some governments may designate certain drugs as orphan drugs. Pharmaceutical companies may be encouraged to invest in developing rare condition therapies due to this designation, which may result in regulatory incentives such as reduced fees and extended market exclusivity. Governments may make investments to upgrade the healthcare infrastructure, including specialized clinics and facilities for identifying and managing uncommon illnesses like amyloidosis. Expanded access to treatments is made possible by improved infrastructure.

Competitive Landscape

Key Players

Several major competitors exist in the fiercely competitive global amyloidosis therapeutic treatment market. The following are a few of the leading market participants and their market shares:

• Prothena Corporation Plc.
• Eidos Therapeutics
• Pfizer Inc.
• SOM Biotech
• Corino Therapeutics
• Johnson and Johnson Services, Inc.
• AstraZeneca Plc.
• Alnylam Pharmaceuticals, Inc.
• GlaxoSmithKline, Plc.
• Others

To remain competitive, these companies prioritize product innovation, distribution channel expansion, mergers, and acquisitions.

The largest suppliers in the global amyloidosis therapeutic treatment market continuously work to keep one step ahead of the competition by developing innovative concepts and products.

In February 2023, Dicerna Pharmaceuticals purchased Entos Pharmaceuticals, a clinical-stage biopharmaceutical business offering RNA interference (RNAi) therapeutics for amyloidosis. This acquisition expanded Dicerna's therapy options for amyloidosis.

In January 2023, Astellas Pharma purchased Swiss biopharmaceutical company Polyphor International, which specializes in treating amyloidosis. Astellas aimed to advance the development of PPH20, a small molecule that inhibits the formation of amyloid fibrils, and strengthen its position in the amyloidosis market.

Summary of Key Findings

• The market for amyloidosis therapeutic treatment continues to be influenced by a growing continuous innovation and development of advanced technologies.
• The market is segmented by type of amyloidosis, treatment modalities, disease severity, and region.
• The market's most popular type of amyloidosis is AL amyloidosis (primary amyloidosis).
• Chemotherapy is the foremost category.
• Newly diagnosed patients are expected to grow fastest regarding CAGR during the forecast period.
• North America is leading market development; the market is highly competitive with key players including Prothena Corporation Plc., Eidos Therapeutics, Pfizer Inc., SOM Biotech, Corino Therapeutics, Johnson and Johnson Services, Inc., AstraZeneca Plc., Alnylam Pharmaceuticals, Inc., GlaxoSmithKline, Plc., and Others.

Future Outlook

• The amyloidosis therapeutic treatment industry is expected to increase significantly in North America and has a positive outlook worldwide.
• The developments in utilizing machine learning for drug discovery support expanding the global market.
• A lack of awareness will hinder the market's growth for amyloidosis therapeutic treatment during the anticipated period.
• To stay ahead of the competition, key enterprises must develop new products, expand their market reach, and keep their prices competitive.

How CXOs Can Benefit from the Credence Research Amyloidosis Therapeutic Treatment Market Report

CXOs may get a detailed picture of the market in the Credence Research Amyloidosis Therapeutic Treatment Market Report, which includes:

• Market size and growth forecast: The report provides detailed estimates of the global amyloidosis therapeutic treatment market size, segmented by type of amyloidosis, treatment modalities, disease severity, and region. It also includes forecasts for the market through 2032 based on key trends and drivers.
• Market segmentation: The research report breaks down the market for amyloidosis therapeutic treatment into segments based on the type of amyloidosis, treatment modalities, disease severity, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
• Competitive landscape: The research report offers a detailed analysis of the major companies in the amyloidosis therapeutic treatment industry, including information on their business plans, line of products, and earnings. CXOs can use this information to evaluate and identify their competitors.
• Key trends and drivers: The research report identifies and evaluates the main trends and factors influencing the market for amyloidosis therapeutic treatment. CXOs can use this information to make well-informed choices regarding their plans and investments.

CXOs can use the insights from the Credence Research Amyloidosis Therapeutic Treatment Market Report to:

• Identify growth opportunities: With the help of this analysis, CXOs may identify new growth opportunities in the amyloidosis therapeutic treatment sector. For example, the report identifies the growing demand for amyloidosis therapeutic treatment from newly diagnosed patients as a key opportunity.
• Make informed investment decisions: With the help of the report, CXOs can choose amyloidosis treatment wisely. For example, the research study provides information on the critical factors to consider while selecting amyloidosis treatment solutions and evaluating amyloidosis treatment suppliers.
• Develop competitive strategies: The research report can be used by CXOs to develop competitive strategies for their amyloidosis treatment businesses. For example, the research paper outlines the main strategies suppliers of amyloidosis therapeutic treatment utilize to differentiate themselves from competitors.
• Track market developments: CXOs may stay ahead of the curve by tracking market developments with the aid of this research report. For instance, the research report offers insights into the most recent developments and trends in the market for amyloidosis therapeutic treatment.

CXOs seeking to expand their industry knowledge and spot growth prospects will find the Credence Research Amyloidosis Therapeutic Treatment Market Report a useful tool.

Segmentation

• By Type of Amyloidosis
  • AL Amyloidosis (Primary Amyloidosis)
  • ATTR Amyloidosis (Hereditary and Wild-Type)
  • AA Amyloidosis (Secondary Amyloidosis)
• By Treatment Modalities
  • Chemotherapy
  • Immunomodulatory Drugs (IMiDs)
  • Monoclonal Antibodies
  • TTR Stabilizers
  • RNA Interference (RNAi) Therapies
  • Liver Transplantation
  • Supportive Care
• By Disease Severity
  • Newly Diagnosed Patients
  • Relapsed or Refractory Disease
  • Advanced Disease
• By Region
  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Aging Global Population

The increasing number of elderly individuals worldwide is leading to a higher incidence of amyloidosis, particularly age-related forms such as wild-type ATTR, thereby expanding the patient pool and driving demand for therapeutic treatments.

Advancements in Diagnostic and Imaging Technologies

The identification of reliable biomarkers and the development of advanced imaging techniques are enabling earlier and more accurate diagnosis of amyloidosis, which increases the number of patients eligible for timely therapeutic intervention.

Innovation in Drug Discovery and Gene Editing

Progress in drug discovery, including the use of high-throughput screening and gene editing technologies like CRISPR, is facilitating the development of targeted therapies that address the underlying genetic and molecular causes of amyloidosis.

Government and Policy Support for Rare Diseases

Increased government initiatives, such as orphan drug designations, research grants, and improved healthcare infrastructure, are incentivizing pharmaceutical companies to invest in amyloidosis treatments and improving patient access to advanced therapies.

Rising Awareness and Early Diagnosis Initiatives

Efforts by medical organizations and advocacy groups to raise awareness among healthcare professionals and patients are leading to earlier diagnosis and intervention, which supports market growth by expanding the treated population.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.